Veracyte (VCYT) Wolfe Research Healthcare Conference 2025 summary

Company performance and growth strategy

• Revenue is on track to double over four years, with EBITDA margins pacing toward 25% this year, ahead of internal plans.

• Decipher has achieved over 25% volume growth for 14 consecutive quarters, while Afirma has seen year-over-year growth for 13 quarters.

• Sustainable double-digit growth is expected, driven by core products and a growing pipeline, with new products like Prosigna and MRD set to launch next year.

• Focus remains on responsible growth, balancing near-, medium-, and long-term returns, and ensuring strong customer experience during new product launches.

• Diversification is important, but Decipher and Afirma alone can sustain growth for the foreseeable future.

Product performance and market dynamics

• Decipher represents about 60% of sales and is growing over 20% annually, benefiting from underpenetrated markets and strong clinical evidence.

• High-risk and metastatic indications are key growth drivers for Decipher, supported by studies like STAMPEDE and BALANCE.

• Commercial infrastructure for Decipher is optimized, with no immediate need for salesforce expansion.

• Digital pathology is not seen as a threat; Decipher remains the gold standard due to robust evidence and guideline inclusion.

• Afirma continues to grow, with opportunities in market share gains and new indications, and is not considered a mature product yet.

Pipeline and innovation

• MRD platform will launch first in muscle-invasive bladder cancer in the first half of next year, using a whole genome approach for differentiation.

• Plan to add one new MRD indication per year, prioritizing based on infrastructure, evidence, and cohort availability.

• Prosigna launch is targeted for mid-next year, with success measured by data quality, reimbursement, and KOL engagement rather than immediate volume.

• Prosigna aims for guideline inclusion and market share gains, leveraging strong evidence from studies like OPTIMA-Main.

• Standardizing lab workflows on whole transcriptome and genome assays will facilitate future product launches and operational efficiency.